Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on the Long-Term Safety of STAR-0215 for Adults with Hereditary Angioedema

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying hereditary angioedema, a rare genetic condition that causes sudden swelling in various parts of the body, such as the face, hands, and feet. The study will use a treatment called STAR-0215, which is administered as a sterile solution through subcutaneous use, meaning it is injected under the skin. The purpose of the study is to assess the long-term safety and tolerability of this treatment in adults with hereditary angioedema.

Participants in the trial will receive repeat doses of STAR-0215 over a period of time. The study will monitor the occurrence of any adverse events, which are unexpected medical problems that may happen during the trial. Additionally, the study will observe changes in the frequency and severity of hereditary angioedema attacks, as well as the duration of these attacks. The trial will also look at how long it takes for an attack to occur after each dose and the number of days participants remain free from attacks.

Throughout the study, researchers will measure the concentration of STAR-0215 in the body and any changes in plasma kallikrein activity, which is a protein involved in the swelling process. The formation of antibodies against the drug will also be monitored. This trial aims to provide valuable information on the effectiveness and safety of STAR-0215 for individuals living with hereditary angioedema.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial assessment

    Upon joining the trial, an initial assessment is conducted to confirm eligibility. This includes reviewing medical history and confirming a diagnosis of hereditary angioedema (HAE).

    Eligibility is based on specific criteria, such as age and previous participation in related studies. For those new to STAR-0215, a documented history of HAE and specific laboratory tests are required.

  2. Step 2

    Baseline evaluation

    A baseline evaluation is performed to establish a starting point for the trial. This involves measuring the frequency and severity of HAE attacks before starting the treatment.

    The evaluation helps in comparing changes during the trial period.

  3. Step 3

    Treatment administration

    The study drug, STAR-0215, is administered as a sterile solution through subcutaneous use. The dosage and frequency are determined by the study protocol.

    The primary goal is to assess the long-term safety and tolerability of the drug in managing HAE.

  4. Step 4

    Monitoring and follow-up

    Regular monitoring is conducted to track the incidence of adverse events and changes in the frequency and severity of HAE attacks.

    Participants are observed for any side effects and the effectiveness of the treatment in reducing HAE attacks.

  5. Step 5

    End of treatment evaluation

    At the end of the treatment period, a comprehensive evaluation is performed to assess the overall impact of the drug.

    This includes measuring the number of HAE attack-free days and any changes in plasma kallikrein activity.

  6. Step 6

    Final assessment

    A final assessment is conducted to determine the formation of any anti-drug antibodies and to evaluate the long-term safety of the treatment.

    The trial aims to conclude by March 31, 2031, with ongoing assessments throughout the study period.

Who can join the trial?

7 criteria

  • Must be at least 18 years old at the time of screening.
  • If previously participated in the STAR-0215-201 study, must have completed all visits through 6 months after the last dose, or met specific criteria related to participation and consultation with the Medical Monitor.
  • If new to the STAR-0215 study and not enrolled in STAR-0215-201, must have a documented diagnosis of **Hereditary Angioedema (HAE)**, which is a condition causing episodes of swelling.
  • Must have a clinical history consistent with HAE, such as swelling episodes without itching.
  • Must have experienced the first symptoms of angioedema at age 30 or younger, or have a family history of HAE.
  • Must have specific levels of a protein called **C1-esterase inhibitor (C1-INH)**, which is involved in controlling swelling. These levels will be tested during screening.
  • If new to the STAR-0215 study, must have had at least 2 HAE attacks during the Run-In Period, confirmed by a study investigator.

Who cannot join the trial?

4 criteria

  • Individuals who do not have a diagnosis of **Hereditary Angioedema**. This is a rare genetic condition that causes sudden swelling in different parts of the body.
  • Participants who are not within the specified age range for the study.
  • Individuals who are part of a vulnerable population, which means they might need special protection or care.
  • Participants who do not meet other specific health criteria set by the study.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

STAR-0215 is a medication being studied for its safety and effectiveness in treating hereditary angioedema, a condition that causes sudden swelling in different parts of the body. This trial is focused on understanding how well patients tolerate the medication over a long period and whether it helps in managing the symptoms of hereditary angioedema.

What is already known about the treatment

STAR-0215 – This medication is administered through injections and is currently being studied in clinical trials for its safety and effectiveness in treating hereditary angioedema, a rare genetic condition. It is in the experimental phase, with ongoing research to determine its long-term safety and tolerability. The main therapeutic indication for STAR-0215 is to prevent and manage symptoms of hereditary angioedema. At the molecular level, it works by inhibiting specific proteins involved in the inflammatory process that leads to swelling. STAR-0215 is classified as a monoclonal antibody, which targets and neutralizes specific molecules in the body to reduce the frequency and severity of angioedema attacks.

Investigated diseases

Hereditary Angioedema – Hereditary Angioedema is a genetic disorder characterized by recurrent episodes of severe swelling. This swelling can occur in various parts of the body, including the hands, feet, face, and airway. The condition is caused by a deficiency or dysfunction of a protein called C1 inhibitor, which leads to an overproduction of bradykinin, a peptide that increases blood vessel permeability. Swelling episodes can be triggered by stress, trauma, or hormonal changes, but they often occur without a clear cause. The frequency and severity of attacks can vary widely among individuals. Swelling in the airway can be particularly dangerous, requiring immediate medical attention.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2023-506540-16-01Protocol codeSTAR-0215-202Estimated enrolment61 patientsSponsorAstria Therapeutics Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).